-
甲状腺功能亢进症(简称甲亢)是由甲状腺本身的甲状腺激素合成和分泌过度引起的甲状腺毒症[1],我国成年人甲亢的发病率为0.78% [2]。目前,131I治疗是甲亢的重要治疗方法[3],由于其快速简便且安全有效,故已经成为国内外甲亢患者的首选治疗方法。然而,131I治疗过程中的放射性会对患者周围的人群和环境造成一定危害。目前,关于131I治疗的辐射剂量研究多针对甲状腺癌患者,而针对甲亢患者的相关研究较少。131I治疗格雷夫斯甲亢指南(2021版)[4]规定,患者体内131I滞留剂量<400 MBq方可出院。临床上大部分甲亢患者服用131I的剂量较低,且均在门诊行131I治疗,这导致其治疗后无住院隔离时间,如果没有进行正确防护,则可能对其家属和公众造成辐射危害。因此,甲亢患者131I治疗的辐射安全问题值得关注。本研究探讨甲亢患者131I治疗后周围剂量当量率的变化及其影响因素,以期为辐射防护提供理论依据。
-
42例甲亢患者的甲状腺摄碘率为(89.18±10.65)%、131I的有效半衰期为(5.76±1.52) d、服药剂量为(327.45±162.43) MBq。
-
由表1可知,甲亢患者131I治疗后2、4周,随着测量距离的增加,周围剂量当量率逐渐降低。以周围剂量当量率<25 μSv/h作为可接触公众人群的标准[5],由表2可知,131I治疗后2周,距离患者≥2.0 m处,周围剂量当量率均<25 μSv/h;131I治疗后4周,距离患者≥0.3 m处,周围剂量当量率均<25 μSv/h。
时间 0 m 0.3 m 1.0 m 2.0 m 4.0 m 131I治疗后2周 882.00±1446.95 26.84±21.49 4.86±17.18 0.78±0.50 0.33±0.12 131I治疗后4周 69.58±40.37 2.60±2.03 0.42±0.24 0.23±0.07 0.20±0.02 表 1 42例甲亢患者131I治疗后2、4周不同测量距离处的周围剂量当量率(
,μSv/h)$\bar x \pm s $ Table 1. Ambient dose equivalent rates of different measurement distances at 2 and 4 weeks after 131I treatment in 42 patients with hyperthyroidism (
, μSv/h)$\bar x \pm s $ 时间 0 m 0.3 m 1.0 m 2.0 m 4.0 m 131I治疗后2周 0(0) 21(50) 41(98) 42(100) 42(100) 131I治疗后4周 5(12) 42(100) 42(100) 42(100) 42(100) 表 2 42例甲亢患者中131I治疗后2、4周不同测量距离处周围剂量当量率<25 μSv/h的患者数[例(%)]
Table 2. The numbers of patients with ambient dose equivalent rate <25 μSv/h of different measurement distances at 2 and 4 weeks after 131I treatment among 42 patients with hyperthyroidism [ cases (%)]
-
由表3可知,不同性别的甲亢患者131I治疗后2、4周,不同测量距离处的周围剂量当量率的差异均无统计学意义(均P>0.05)。
测量距离(m) 131I治疗后2周 131I治疗后4周 男性(n=12) 女性(n=30) t值 P值 男性(n=12) 女性(n=30) t值 P值 0 715.53±321.70 948.59±1704.32 −0.467 0.643 76.59±44.51 66.78±39.04 0.707 0.483 0.3 33.39±23.83 24.23±20.32 1.257 0.216 3.42±2.01 2.28±1.98 1.680 0.101 1.0 12.26±31.80 1.89±1.48 1.129 0.283 0.46±0.23 0.40±0.25 0.744 0.461 2.0 1.05±0.71 0.67±0.34 1.766 0.101 0.24±0.04 0.22±0.08 0.565 0.575 4.0 0.37±0.16 0.31±0.11 1.244 0.221 0.20±0.01 0.20±0.03 0.422 0.675 表 3 42例不同性别的甲亢患者131I治疗后2、4周不同测量距离处的周围剂量当量率(
,μSv/h)$ \bar x \pm s $ Table 3. Ambient dose equivalent rates of different measurement distances at 2 and 4 weeks after 131I treatment in 42 patients with hyperthyroidism of different genders (
, μSv/h)$ \bar x \pm s $ -
由表4可知,甲亢患者131I治疗后2周,测量距离为0、0.3、4.0 m处的周围剂量当量率均与131I的有效半衰期呈正相关(均P<0.05);测量距离为2.0、4.0 m处的周围剂量当量率均与服药剂量呈正相关(均P<0.01);不同测量距离处的周围剂量当量率与患者的年龄和甲状腺摄碘率均无相关性(均P>0.05)。
指标 0 m 0.3 m 1.0 m 2.0 m 4.0 m r值 P值 r值 P值 r值 P值 r值 P值 r值 P值 年龄 −1.158 0.317 −0.211 0.181 0.117 0.460 −0.283 0.070 −0.261 0.095 甲状腺摄碘率 0.067 0.673 0.162 0.306 0.159 0.314 −0.182 0.247 −0.098 0.538 131I的有效半衰期 0.318 0.040 0.487 0.001 −0.132 0.405 0.299 0.054 0.327 0.035 服药剂量 0.102 0.522 0.194 0.219 0.235 0.133 0.546 <0.001 0.491 0.001 表 4 42例甲亢患者131I治疗后2周不同测量距离处的周围剂量当量率与临床指标的相关性分析
Table 4. Correlation analysis of ambient dose equivalent rate of different measurement distances and clinical indicators in 42 patients with hyperthyroidism 2 weeks after 131I treatment
由表5可知,甲亢患者131I治疗后4周,测量距离为0 m处的周围剂量当量率与年龄呈正相关(P<0.01);测量距离为0、0.3、1.0、2.0 m处的周围剂量当量率均与131I的有效半衰期呈正相关(均P<0.05);测量距离为2.0 m处的周围剂量当量率与甲状腺摄碘率呈正相关(P<0.05);不同测量距离处的周围剂量当量率与服药剂量均无相关性(均P>0.05)。
指标 0 m 0.3 m 1.0 m 2.0 m 4.0 m r值 P值 r值 P值 r值 P值 r值 P值 r值 P值 年龄 0.429 0.005 0.274 0.079 0.250 0.111 −0.102 0.519 −0.249 0.112 甲状腺摄碘率 0.155 0.326 0.042 0.793 0.253 0.106 0.353 0.022 −0.003 0.986 131I的有效半衰期 0.319 0.039 0.363 0.018 0.376 0.014 0.380 0.013 0.188 0.234 服药剂量 0.095 0.549 0.100 0.528 0.020 0.898 0.025 0.877 0.157 0.321 表 5 42例甲亢患者131I治疗后4周不同测量距离处的周围剂量当量率与临床指标的相关性分析
Table 5. Correlation analysis of ambient dose equivalent rate of different measurement distances and clinical indicators in 42 patients with hyperthyroidism 4 weeks after 131I treatment
甲亢患者131I治疗后周围剂量当量率的变化及其影响因素的研究
Study on the changes of ambient dose equivalent rate and its influencing factors in patients with hyperthyroidism after 131I treatment
-
摘要:
目的 探讨甲状腺功能亢进症(甲亢)患者131I治疗后周围剂量当量率的变化及其影响因素,为辐射防护提供理论依据。 方法 回顾性分析2018年10月至2019年11月于重庆医科大学附属第一医院行131I治疗的42例甲亢患者的临床资料,其中男性12例、女性30例,年龄14~68(38.7±11.9)岁。测量131I治疗后2、4周距离患者颈部正前方0、0.3、1.0、2.0、4.0 m处的周围剂量当量率,分析其变化规律,并探讨患者的性别、年龄、甲状腺摄碘率、131I的有效半衰期及服药剂量与周围剂量当量率的相关性。2组间计量资料的比较采用独立样本t检验,周围剂量当量率与各指标之间的相关性采用Pearson相关性分析。 结果 所有甲亢患者131I治疗后2、4周的周围剂量当量率随测量距离的增加逐渐降低。131I治疗后2周,距离患者≥2.0 m处,周围剂量当量率均<25 μSv/h;131I治疗后4周,距离患者≥0.3 m处,周围剂量当量率均<25 μSv/h。不同性别患者不同测量距离处的周围剂量当量率间的差异均无统计学意义(t=−0.467~1.766,均P>0.05)。131I治疗后2周,测量距离为0、0.3、4.0 m处的周围剂量当量率均与131I的有效半衰期呈正相关(r=0.318~0.487,均P<0.05);测量距离为2.0、4.0 m处的周围剂量当量率均与服药剂量呈正相关(r=0.546、0.491,均P<0.01);不同测量距离处的周围剂量当量率与患者的年龄和甲状腺摄碘率均无相关性(r=−1.158~0.162,均P>0.05)。131I治疗后4周,测量距离为0、0.3、1.0、2.0 m处的周围剂量当量率均与131I的有效半衰期呈正相关(r=0.319~0.380,均P<0.05);测量距离为0 m处的周围剂量当量率与患者的年龄呈正相关(r=0.429,P<0.01);测量距离为2.0 m处的周围剂量当量率与甲状腺摄碘率呈正相关(r=0.353,P<0.05);不同测量距离处的周围剂量当量率与服药剂量均无相关性(r=0.020~0.157,均P>0.05)。 结论 甲亢患者131I治疗后4周内应尽量避免与家属亲密接触,临床医师应根据周围剂量当量率的测量结果及131I在患者体内的有效半衰期对甲亢患者的居家隔离进行辐射防护指导。 Abstract:Objective To investigate the changes in ambient dose equivalent rate and its influencing factors in patients with hyperthyroidism after 131I treatment to provide a theoretical basis for radiation protection. Methods The clinical data of 42 patients with hyperthyroidism who received 131I treatment in the First Affiliated Hospital of Chongqing Medical University from October 2018 to November 2019 were retrospectively analyzed. The patients included 12 males and 30 females aged 14–68 (38.7±11.9) years old. The ambient dose equivalent rates at 0, 0.3, 1.0, 2.0 and 4.0 m from the front of the neck of the patient were measured at 2 and 4 weeks after 131I treatment, and their trends were analyzed. The correlations among the gender, age, thyroid iodine uptake rate, effective half-life of 131I , medication dose, and ambient dose equivalent rate of the patients were also investigated. The measurement data were compared between the two groups via independent samples t test, and the correlation between the ambient dose equivalent rate and each index was analyzed through Pearson correlation analysis. Results The ambient dose equivalence rate decreased gradually with the increase in the measurement distance at 2 and 4 weeks after 131I treatment. At 2 weeks after 131I treatment and distance ≥ 2.0 m from the patients, the ambient dose equivalent rates were all <25 μSv/h. At 4 weeks after 131I treatment and distance ≥ 0.3 m from the patients, the ambient dose equivalent rates were all <25 μSv/h. There was no significant difference in the ambient dose equivalent rates at different measurement distances in patients of different genders (t=−0.467–1.766, all P>0.05). At 2 weeks after 131I treatment, the ambient dose equivalent rates measured at distances of 0, 0.3, and 4.0 m were positively correlated with the effective half-life of 131I (r=0.318–0.487, all P<0.05); the ambient dose equivalent rates measured at distances of 2.0 and 4.0 m were positively correlated with the medication dose (r=0.546, 0.491; both P<0.01); the ambient dose equivalent rates at different measurement distances had no correlation with the patients' age and thyroid iodine uptake rate (r=−1.158–0.162, all P>0.05). At 4 weeks after 131I treatment, the ambient dose equivalent rates measured at distances of 0, 0.3, 1.0 and 2.0 m were positively correlated with the effective half-life of 131I (r=0.319–0.380, all P<0.05); the ambient dose equivalent rate measured at distances of 0 m was positively correlated with the patients' age (r=0.429, P<0.01); the ambient dose equivalent rate measured at distances of 2.0 m was positively correlated with the thyroid iodine uptake rate (r=0.353, P<0.05); the ambient dose equivalent rates at different measurement distances had no correlation with the medication dose (r=0.020–0.157, all P>0.05). Conclusions Patients with hyperthyroidism should try to avoid close contact with their family members within 4 weeks after 131I treatment. Clinicians should provide guidance on radiation protection during the home isolation of patients with hyperthyroidism on the basis of the measurement results of the ambient dose equivalent rate and the effective half-life of 131I in the patients' body. -
表 1 42例甲亢患者131I治疗后2、4周不同测量距离处的周围剂量当量率(
,μSv/h)$\bar x \pm s $ Table 1. Ambient dose equivalent rates of different measurement distances at 2 and 4 weeks after 131I treatment in 42 patients with hyperthyroidism (
, μSv/h)$\bar x \pm s $ 时间 0 m 0.3 m 1.0 m 2.0 m 4.0 m 131I治疗后2周 882.00±1446.95 26.84±21.49 4.86±17.18 0.78±0.50 0.33±0.12 131I治疗后4周 69.58±40.37 2.60±2.03 0.42±0.24 0.23±0.07 0.20±0.02 表 2 42例甲亢患者中131I治疗后2、4周不同测量距离处周围剂量当量率<25 μSv/h的患者数[例(%)]
Table 2. The numbers of patients with ambient dose equivalent rate <25 μSv/h of different measurement distances at 2 and 4 weeks after 131I treatment among 42 patients with hyperthyroidism [ cases (%)]
时间 0 m 0.3 m 1.0 m 2.0 m 4.0 m 131I治疗后2周 0(0) 21(50) 41(98) 42(100) 42(100) 131I治疗后4周 5(12) 42(100) 42(100) 42(100) 42(100) 表 3 42例不同性别的甲亢患者131I治疗后2、4周不同测量距离处的周围剂量当量率(
,μSv/h)$ \bar x \pm s $ Table 3. Ambient dose equivalent rates of different measurement distances at 2 and 4 weeks after 131I treatment in 42 patients with hyperthyroidism of different genders (
, μSv/h)$ \bar x \pm s $ 测量距离(m) 131I治疗后2周 131I治疗后4周 男性(n=12) 女性(n=30) t值 P值 男性(n=12) 女性(n=30) t值 P值 0 715.53±321.70 948.59±1704.32 −0.467 0.643 76.59±44.51 66.78±39.04 0.707 0.483 0.3 33.39±23.83 24.23±20.32 1.257 0.216 3.42±2.01 2.28±1.98 1.680 0.101 1.0 12.26±31.80 1.89±1.48 1.129 0.283 0.46±0.23 0.40±0.25 0.744 0.461 2.0 1.05±0.71 0.67±0.34 1.766 0.101 0.24±0.04 0.22±0.08 0.565 0.575 4.0 0.37±0.16 0.31±0.11 1.244 0.221 0.20±0.01 0.20±0.03 0.422 0.675 表 4 42例甲亢患者131I治疗后2周不同测量距离处的周围剂量当量率与临床指标的相关性分析
Table 4. Correlation analysis of ambient dose equivalent rate of different measurement distances and clinical indicators in 42 patients with hyperthyroidism 2 weeks after 131I treatment
指标 0 m 0.3 m 1.0 m 2.0 m 4.0 m r值 P值 r值 P值 r值 P值 r值 P值 r值 P值 年龄 −1.158 0.317 −0.211 0.181 0.117 0.460 −0.283 0.070 −0.261 0.095 甲状腺摄碘率 0.067 0.673 0.162 0.306 0.159 0.314 −0.182 0.247 −0.098 0.538 131I的有效半衰期 0.318 0.040 0.487 0.001 −0.132 0.405 0.299 0.054 0.327 0.035 服药剂量 0.102 0.522 0.194 0.219 0.235 0.133 0.546 <0.001 0.491 0.001 表 5 42例甲亢患者131I治疗后4周不同测量距离处的周围剂量当量率与临床指标的相关性分析
Table 5. Correlation analysis of ambient dose equivalent rate of different measurement distances and clinical indicators in 42 patients with hyperthyroidism 4 weeks after 131I treatment
指标 0 m 0.3 m 1.0 m 2.0 m 4.0 m r值 P值 r值 P值 r值 P值 r值 P值 r值 P值 年龄 0.429 0.005 0.274 0.079 0.250 0.111 −0.102 0.519 −0.249 0.112 甲状腺摄碘率 0.155 0.326 0.042 0.793 0.253 0.106 0.353 0.022 −0.003 0.986 131I的有效半衰期 0.319 0.039 0.363 0.018 0.376 0.014 0.380 0.013 0.188 0.234 服药剂量 0.095 0.549 0.100 0.528 0.020 0.898 0.025 0.877 0.157 0.321 -
[1] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医疗保健国际交流促进会临床实用技术分会. 甲状腺功能亢进症外科治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(11): 1229−1233. DOI: 10.19538/j.cjps.issn1005-2208.2020.11.01.
Chinese Thyroid Association, Chinese Collage of Surgeons, Chinese Medical Doctor Association, Chinese Research Hospital Association Thyroid Disease Committee, Clinical Practical Technology Committee of China International Exchange and Promotive Association for Medical and Health Care. Chinese expert consensus on surgical treatment of hyperthyroidism (2020 edition)[J]. Chin J Pract Surg, 2020, 40(11): 1229−1233. DOI: 10.19538/j.cjps.issn1005-2208.2020.11.01.[2] Li YZ, Teng D, Ba JM, et al. Efficacy and safety of long-term universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China[J]. Thyroid, 2020, 30(4): 568−579. DOI: 10.1089/thy.2019.0067. [3] 邢岩. 放射性核素碘131治疗Graves甲状腺功能亢进的研究进展[J]. 上海医药, 2021, 42(14): 3−6. DOI: 10.3969/j.issn.1006-1533.2021.14.002.
Xing Y. Research progress of radionuclide 131 iodine in the treatment of Graves hyperthyroidism[J]. Shanghai Med Pharm J, 2021, 42(14): 3−6. DOI: 10.3969/j.issn.1006-1533.2021.14.002.[4] 中华医学会核医学分会. 131I治疗格雷夫斯甲亢指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 242−253. DOI: 10.3760/cma.j.cn321828-20201109-00405.
Chinese Society of Nuclear Medicine. Clinical guidelines for 131I treatment of Graves' hyperthyroidism (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 242−253. DOI: 10.3760/cma.j.cn321828-20201109-00405.[5] 国家卫生健康委员会. GBZ 120−2020核医学放射防护要求[S]. 北京: 中国标准出版社, 2020.
National Health Commission of the People's Republic of China. GBZ 120−2020 requirements for radiological protection in nuclear medicine[S]. Beijing: Standards Press of China, 2020.[6] 甘景文. 碘131和抗甲状腺药物治疗甲状腺功能亢进症的进展[J]. 中外医学研究, 2020, 18(18): 178−180. DOI: 10.14033/j.cnki.cfmr.2020.18.074.
Gan JW. Progress of iodine 131 and antithyroid drugs in the treatment of hyperthyroidism[J]. Chin Foreign Med Res, 2020, 18(18): 178−180. DOI: 10.14033/j.cnki.cfmr.2020.18.074.[7] Canto AU, Dominguez PN, Jimeno CA, et al. Comparison of fixed versus calculated activity of radioiodine for the treatment of Graves disease in adults[J]. Endocrinol Metab (Seoul), 2016, 31(1): 168−173. DOI: 10.3803/EnM.2016.31.1.168. [8] 王荣福, 安锐. 核医学[M]. 北京: 人民卫生出版社, 2018.
Wang RF, An R. Nuclear medicine[M]. Beijing: People's Medical Publishing House, 2018.[9] 凌攀, 倪红珍, 杨柳莹, 等. 2014−2018年四川省从事放射性工作人员染色体畸变率分析[J]. 预防医学情报杂志, 2019, 35(11): 1290−1293.
Ling P, Ni HZ, Yang LY, et al. Analysis on chromosome aberration rate of radioactive practitioners in Sichuan Province from 2014 to 2018[J]. J Prev Med Inf, 2019, 35(11): 1290−1293.[10] 姚叶豹, 马得勋, 殷爱民, 等. 低剂量电离辐射对人体健康影响的研究现状[J]. 辐射防护通讯, 2020, 40(3): 1−8, 24. DOI: 10.3969/j.issn.1004-6356.2020.03.001.
Yao YB, Ma DX, Yin AM, et al. Research progress on effects of low dose ionizing radiation on human health[J]. Radiat Prot Bull, 2020, 40(3): 1−8, 24. DOI: 10.3969/j.issn.1004-6356.2020.03.001.[11] Kamiya K, Ozasa K, Akiba S, et al. Long-term effects of radiation exposure on health[J]. Lancet, 2015, 386(9992): 469−478. DOI: 10.1016/S0140-6736(15)61167-9. [12] 王萧, 焦玲, 张桂芝, 等. 甲亢患者碘治疗后131I滞留量与周围剂量当量率的关系[J]. 辐射研究与辐射工艺学报, 2015, 33(5): 050203. DOI: 10.11889/j.1000-3436.2015.rrj.33.050203.
Wang X, Jiao L, Zhang GZ, et al. Study on retained body activity and external dose rate of patients receiving 131I therapy for hyperthyroidism[J]. J Radiat Res Radiat Process, 2015, 33(5): 050203. DOI: 10.11889/j.1000-3436.2015.rrj.33.050203.[13] Liu B, Tian R, Peng WA, et al. Radiation safety precautions in 131I therapy of Graves' disease based on actual biokinetic measurements[J]. J Clin Endocrinol Metab, 2015, 100(8): 2934−2941. DOI: 10.1210/jc.2015-1682. [14] ICRP. Release of patients after therapy with unsealed radionuclides[R]. ICRP Publication 94, Amsterdam: Elsevier, 2004. [15] 张晓懿, 涂彧. 甲亢患者131I治疗后人体周围辐射场剂量分布[J]. 中国辐射卫生, 2013, 22(1): 36−38. DOI: 10.13491/j.cnki.issn.1004-714x.2013.01.023.
Zhang XY, Tu Y. Dose distribution of radiation around human body in hyperthyroidism patients after 131I therapy[J]. Chin J Radiol Health, 2013, 22(1): 36−38. DOI: 10.13491/j.cnki.issn.1004-714x.2013.01.023.[16] Cui SY, Jiao L, Tan J, et al. Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients[J]. Health Phys, 2014, 106(3): 365−369. DOI: 10.1097/HP.0b013e3182a1c8d5. [17] 康增寿, 李方, 林岩松. 开放性放射性核素治疗后患者免住院的建议(ICRP 94 报告要点解读)[J]. 国际放射医学核医学杂志, 2019, 43(5): 397−399. DOI: 10.3760/cma.j.issn.1673-4114.2019.05.002.
Kang ZS, Li F, Lin YS. Release of patients therapy with unsealed radionuclides (ICRP publication 94)[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 397−399. DOI: 10.3760/cma.j.issn.1673-4114.2019.05.002.